Serum interleukin 15 levels in patients with seropositive myasthenia gravis do not correlate with disease severity.
Sign Up to like & getrecommendations! Published in 2018 at "Neurologia i neurochirurgia polska"
DOI: 10.1016/j.pjnns.2017.12.011
Abstract: AIM To assess interleukin 15 (IL-15) serum levels in patients with seropositive myasthenia gravis (MG); searching for potential relationship between IL-15 levels and clinical features such as gender, age at onset, clinical presentation or treatment… read more here.
Keywords: levels patients; serum levels; myasthenia gravis; seropositive myasthenia ... See more keywords
Effectiveness of treatment for 31 patients with seropositive autoimmune autonomic ganglionopathy in Japan
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Neurological Disorders"
DOI: 10.1177/17562864221110048
Abstract: Background: Autoimmune autonomic ganglionopathy (AAG) is characterized by serum autoantibodies against the ganglionic acetylcholine receptor (gAChR). Immunomodulatory treatments may alleviate AAG symptoms, but the most appropriate treatment strategy is unclear. Objective: This study aimed to… read more here.
Keywords: autonomic ganglionopathy; seropositive aag; patients seropositive; autoimmune autonomic ... See more keywords
Soluble glycoprotein VI, a specific marker of platelet activation is increased in the plasma of subjects with seropositive rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "PLoS ONE"
DOI: 10.1371/journal.pone.0188027
Abstract: Objectives Anti-citrullinated protein antibodies (ACPA) have been shown to cause platelet activation in vitro, through the low-affinity immunoglobulin G (IgG) receptor (FcγRIIa) on platelets. Platelet activation via engagement of FcγRIIa results in proteolytic cleavage and… read more here.
Keywords: specific marker; platelet activation; activation; sgpvi ... See more keywords